Fluticasone propionate protects against ozone-induced airways inflammation and modified immune cell activation markers in healthy volunteers

Environmental Health Perspectives

Volumn 116, Issue 6, 2008, Pages 799-805

  Alexis, Neil E ^a   Lay, John C ^a   Haczku, Angela ^b   Gong, Henry ^c,d   Linn, William ^c,d   Hazucha, Milan J ^a   Harris, Brad ^a   Tal Singer, Ruth ^e   Peden, David B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c South Carolina University   (United States)

^d RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Inhaled corticosteroids; Innate immune marker; Ozone; Spurum neutrophils

Indexed keywords

BIOLOGICAL MARKER; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD64 ANTIGEN; CD86 ANTIGEN; CELL SURFACE MARKER; CLARA CELL PROTEIN; CLARA CELL PROTEIN 16; FLUTICASONE PROPIONATE; HLA DR ANTIGEN; NITRIC OXIDE; OZONE; PLACEBO;

ADULT; ARTICLE; BREATH ANALYSIS; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LUNG FUNCTION TEST; MALE; MONOCYTE; MULTICENTER STUDY; NEUTROPHIL COUNT; NEUTROPHILIA; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SINGLE DRUG DOSE; SPUTUM CULTURE; UNSPECIFIED SIDE EFFECT;

ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD11B; ANTIGENS, CD86; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; INFLAMMATION; LUNG; MALE; NEUTROPHILS; OZONE; RECEPTORS, IGG; SPUTUM;

EID: 46749121056     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.10981     Document Type: Article

References (37)

1. Alexis NE, Becker S, Bromberg PA, Devlin R. Peden DB. 2004a. Circulating CD11b expression correlates with the neutrophil response and airway mCD14 expression is enhanced following ozone exposure in humans. Clin Immunol 111(1):126-131.
2. Alexis NE, Eldridge MW, Peden DB. 2003. Effect of inhaled endotoxin an airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol 112(2):353-361.
3. Alexis NE, Eldridge MW, Peden DB. 2OD4b. Effect af inhaled endotoxin on airway and circulating inflammatory cell phagacytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol 12:353-361.
4. Alexis NE, Lay JC, Zeman K, Bennett WE, Peden DB, Soukup JM, et al. 2006. Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers. J Allergy Clin Immunol 117:1396-1403.
5. Alexis NE, Peden DB. 2001. Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: a role for CD14. J Allergy Clin Immunol 108:577-580.
6. Alexis N, Soukup J, Ghio A, Becker S. 2000a. Sputum phagocytes from healthy individuals are functional and activated: a flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood. Clin Immunol 97:21-32.
7. Alexis N. Urch B, Tarlo S, Corey P, Pengelly D, O'Byrne P, et al. 2000b. Cyclooxygenase metabolites play a different role in ozone-induced pulmonary function decline in asthmatics compared to normals. Inhal Toxicol 12(12):1205-1224.
8. American Thoracic Society and European Respiratory Society. 2005. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 171(8):912-930.
9. Bernstein JA, Alexis N, Barnes C, Bernstein IL, Nel A, Peden D, et al. 2004. Health effects of air pollution. J Allergy Clin Immunol 114:1116-1123.
10. Blomberg A, Mudway IS, Nordenhall C, Hedenstrom H, Kelly FJ, Frew AJ, et al. 1999. Ozone-induced lung function decrements do not correlate with early airway inflammatory or antioxidant responses. Eur Respir J 13(6): 1418-1428.
11. Blomberg A. Mudway I, Svensson M, Hagenbjork-Gustafsson A, Thomasson L, Helleday R, et al. 2003. Clara cell protein as a biomarker for ozone-induced lung injury in humans. Eur Respir J 22:883-888.
12. Cao Y, Tao JO, Bates SR, Beers MF, Haczku A. 2004. IL-4 induces production of the lung collectin surfactant protein-D. J Allergy Clin Immunol 113(3):439-444.
13. Enright PL. 2003. How to make sure your spirometry tests are of good quality. Respir Care 48:773-776.
14. Gong H, Wong R, Sarma RJ, Linn WS, Sullivan ED, Shamoo DA, et al. Cardiovascular effects of ozone exposure in human volunteers. 1998. Am J Respir Crit Care Med 158(2):538-546.
15. Haczku A. 2006. Role and regulation of lung collectins in allergic airway sensitization. Pharmacol Ther 110(1):14-34.
16. Hazucha MJ, Madden M, Pape G, Becker S, Devlin R, Koren HS, et al. 1996. Effects of cyclo-oxygenase inhibition on ozone-induced respiratory inflammation and lung function changes. Eur J Appl Physiol Occup Physiol 73(1-2):17-27.
17. Helleday R, Sagerstedt B, Forsberg B, Mudway I, Nordberg G, Bernard A, et al. 2006. Exploring the time dependence of serum Clara cell protein as a biomarker of pulmonary injury in humans. Chest 130:672-675.
18. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. 1999. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with α-antitrypsin deficiency. J Respir Crit Care Med 160:1968-1975.
19. Holz O, Jorres FA, Timm P, Mucke M, Richter K, Koschyk S, et al. 1999. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med 159:776-784.
20. Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, et al. 2005. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol 45: 498-503.
21. Kierstein S, Poulain FR, Cao Y, Grous M, Mathias R. Kierstein G, et al. 2006. Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D. Respir Res 7:85; doi:10.1186/1465-9921-7-85 [Online 1 June 2006].
22. Koike E. Kobayashi T. 2004. Ozone exposure enhances antigen-presenting activity of interstitial lung cells in rats. Toxicology 196:217-227.
23. Lakind JS, Holgate ST, Ownby DR, Mansur AH, Helms PJ. Pyatt D, et al 2007. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker at acute or chronic pulmonary effects. Biomarkers 12(5):445-467.
24. Lay JC, Alexis NE, Kleeberger SR, Roubey RAS, Harris BD, Bromberg PA, et al. 2007. Ozone exposure enhances expression of surface markers of innate immunity and antigen presentation on airway monocytes in healthy individuals. J Allergy Clin Immunol 120(3):719-722.
25. Louis R, Lou LCK, Bron AD, Roldaan AC, Radermecker M, Djukanovi R. 2000. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161:9-16.
26. Maneechotesuwan K, Essílfie-Quaye S, Kharitonov SA, Adcock IM, Barnes PJ. 2007. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. Chest 132(1):98-105.
27. McDonnell WF, Stewart PW, Andreoni S, Seal E Jr, Kehrl HR, Horstman DH, et al. 1997, Prediction of ozone-induced FEV, changes. Effects of concentration, duration, and vantilation. Am J Respir Crit Care Med 156:715-722.
28. Michel O, Murdoch R, Bernard A. 2005. Inhaled LPS induces blood release of Clara cell specific protein (CC16) in human beings. J Allergy Clin Immunol 115:1143-1147.
29. Nightingale JA, Rogers OF, Fan CK, Barnes PJ. 2000. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med 161:479-486.
30. Pauwels RA. 2004. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 1(2):73-76.
31. Peden DB. 2001. Air pollution in asthma: effect of pollutants on airway inflammation. Ann Allergy Asthma Immunol 87:12-17.
32. Scannell C, Chan L, Aris RM, Tager I, Christian D, Ferrando R, et al. 1996. Greater ozone-induced inflammatory responses in subjects with asthma. Am J Respir Crit Care Med 154(1):24-29.
33. Singh R, Tal-Singer R, Faiferman I, Lasenby S. Henderson A, Wessels D, et al. 2006. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomised, double blind, placebo controlled, crossover study in healthy subjects. Br J Clin Pharm 61(4):398-404.
34. Stockley RA. 1998. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax 53:58-62.
35. Vagaggini B, Taccola M, Conti I, Carnevali S, Cianchetti S, Bartuli ML, et al. 2001. Budesonide reduces neutrophilic but not functional airway response to ozone in mild asthmatics. Am J Respir Crit Care Med 164:2172-2176.
36. Wenzel S. 2003. Severe/fatal asthma. Chest 123:405S-410S.
37. Wenzel SE, Schwartz LB, Longmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. 1999. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160:1001-1008.